Recent Submissions

SmallCapReview.com has been a leading site for information on small cap stocks, penny stocks and microcaps since 1999.

BioSante Pharmaceuticals (Nasdaq: BPAX) $3.57. Today announced an exclusive worldwide license of its Melanoma Vaccine to The John P. Hussman Foundation, a charitable foundation that supports research to address life-threatening medical conditions and significant disabilities. BioSante received $100,000 on signing the license and is eligible for up to $39 million in milestone payments, plus royalties on sales. Additionally, the Hussman Foundation has committed up to approximately $11 million in Melanoma Vaccine clinical development funding. Also, BioSante will receive between 15 and 33 percent of any sublicense payments received by the Hussman Foundation depending on the timing of any sublicense by the Foundation to a corporate sub-licensee.

BioSante’s Melanoma Vaccine is one of a portfolio of BioSante cancer vaccines in development including vaccines for leukemia, breast and pancreatic cancer. BioSante’s Melanoma Vaccine was granted Orphan Drug designation by the FDA earlier this year.

What They Do: BioSante is a specialty pharmaceutical company focused on developing products for female sexual health and oncology.

Datalink (Nasdaq: DTLK) $7.91. Announced Wednesday after market close results for its second quarter and six month period that ended June 30, 2011. Revenues for the quarter ended June 30, 2011, increased 26% to $89.5 million compared to $70.9 million for the prior-year period. Revenues for six months ended June 30, 2011, increased 31% to $175.2 million compared to $133.4 million for the six months ended June 30, 2010.

GAAP Results
On a GAAP basis, the company reported net earnings of $2.7 million or $0.16 per diluted share for the second quarter ended June 30, 2011. This compares to break-even in the second quarter of 2010. For the six months ended June 30, 2011, the company reported net earnings of $4.4 million or $0.29 per diluted share, compared to a net loss of $886,000, or $0.07 per diluted share, for the six months ended June 30, 2010.

What They Do: Datalink transforms data centers so they become more efficient, manageable and responsive to changing business needs.

About SmallCapReview

Copyright SmallCapReview. SmallCapReview.com is a leading site for news on small-caps, penny stocks and microcaps. SmallCapReview has built a loyal opt-in following for their investor products by providing a newsletter at no cost, sent to subscribers, highlighting select stocks in play, to register visit www.SmallCapReview.com.